• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cadrenal Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/8/25 4:05:33 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CVKD alert in real time by email
    false 0001937993 0001937993 2025-05-08 2025-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (date of earliest event reported): May 8, 2025

     

    Cadrenal Therapeutics, Inc.

    (Exact name of registrant as specified in charter)

     

    Delaware   001-41596   88-0860746
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    822 A1A North, Suite 306

    Ponte Vedra, Florida 32082

    (Address of principal executive offices and zip code)

     

    (904) 300-0701

    (Registrant’s telephone number including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbols   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   CVKD   The Nasdaq Stock Market LLC
    (Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Condition.

     

    On May 8, 2025, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal quarter ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference.

     

    The information contained in this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    The following exhibits are furnished with this Current Report on Form 8-K:

     

    Exhibit
    Number
      Exhibit Description
         
    99.1   Press Release, issued by Cadrenal Therapeutics, Inc. on May 8, 2025
    104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document)

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: May 8, 2025 CADRENAL THERAPEUTICS, INC.
       
      By: /s/ Quang X. Pham
      Name:

    Quang X. Pham

      Title: Chairman and Chief Executive Officer

     

     

    2

     

    Get the next $CVKD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CVKD

    DatePrice TargetRatingAnalyst
    12/18/2023$4.00Outperform
    Noble Capital Markets
    More analyst ratings

    $CVKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by CEO and Chairman Pham Quang X

      4/A - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

      3/24/25 8:38:14 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Ferguson James J. Iii

      4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

      2/6/25 4:51:35 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Ferguson James J. Iii

      3 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

      2/6/25 4:50:29 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    SEC Filings

    See more
    • Cadrenal Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Shareholder Director Nominations, Other Events, Financial Statements and Exhibits

      8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      7/18/25 4:49:09 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      5/8/25 4:05:33 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Cadrenal Therapeutics Inc.

      10-Q - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      5/8/25 6:17:43 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Leadership Updates

    Live Leadership Updates

    See more
    • Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

      James J. Ferguson, MD, FACC, FAHA, joins as Chief Medical Officer Extensive experience provides strong support for advancing specialized cardiovascular assets, including leading the late-stage clinical development of tecarfarin and other business development opportunities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K antagonist, today announced a leadership transition appointing James J. Ferguson, MD, FACC, FAHA, as its new Chief Medical Officer, effective immediately. Dr. Ferguson is a distinguished medical expert with over 25

      2/6/25 9:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

      Lays out Phase 3 Clinical and Regulatory Path for Tecarfarin and Three-Year Strategic Plan Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January 13-16, 2025 in San Francisco, California. Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist (VKA) in advanced clinical development and designed to be a superior and safer chronic anticoagulant therapeutic for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions. Quang X. Pham, Chairman and Chief

      12/18/24 9:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

      PONTE VEDRA, Fla., Feb. 8, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the appointment of Jeff Cole to the newly created position of Chief Operating Officer. In this role, Mr. Cole will be responsible for the Company's manufacturing and supply chain operations, intellectual property, commercialization strategies, and supporting partnering activities for tecarfarin. Mr. Cole brings over 25 years of

      2/8/24 9:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Financials

    Live finance-specific insights

    See more
    • Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

      Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin Leadership appointments to strengthen development capabilities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December 31, 2024, and provided a business update and highlights of the path forward for the clinical advancement of tecarfarin. "2024 for Cadrenal was a year of

      3/13/25 4:05:00 PM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cadrenal Therapeutics Inc.

      SC 13G/A - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

      11/14/24 4:00:17 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cadrenal Therapeutics Inc.

      SC 13G - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

      10/4/24 4:15:02 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Cadrenal Therapeutics with a new price target

      Noble Capital Markets initiated coverage of Cadrenal Therapeutics with a rating of Outperform and set a new price target of $4.00

      12/18/23 8:12:12 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

      LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39,000 per event Tecarfarin, with its novel metabolic pathway, potentially may offer an alternative to warfarin in this vulnerable population Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing novel therapeutics for patients with cardiovascular disease, today announced new findings from third-party research on the economic and medical burdens faced by advanced heart failure patie

      6/12/25 8:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

      Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced that members of its executive leadership team will be attending and participating in the upcoming BIO International Convention 2025, taking place June 16-19, 2025 in Boston. Cadrenal executives will participate in one-on-one meetings with investors and potential partners to provide key updates on the Company's strategic direction and clinical development of its lead asset, tecarfarin. Those interested in meeting with Cadrenal management should request a meeting through the Conference meeting portal or contact Investor Relations at cadrena

      6/4/25 8:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

      Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug candidate, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant that is designed to address unmet needs in anticoagulation therapy. Cadrenal completed the technical transfer and manufacturing of its tecarfarin drug substance in accordance with current good manufacturing practices (cGMP) earlier this year at a U.S. site of a leading global Contract Development and Manufacturing Organization (CDMO). Manufacturing of the tecarfarin drug product candidate is currently und

      5/15/25 7:30:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care